Status: Excluded due to NICE appraisal | |
Product meets AWMSG exclusion criteria due to NICE appraisal TA422: Crizotinib for previously treated anaplastic lymphoma kinase-positive advanced non-small-cell lung cancer (replaced TA296) |
|
Medicine details |
|
Medicine name | crizotinib (Xalkori®) |
Formulation | 200 mg, 250 mg capsule |
Reference number | 791 |
Indication | Treatment of adults with previously treated anaplastic lymphoma kinase (ALK)-positive advanced non-small cell lung cancer |
Company | Pfizer Ltd |
BNF chapter | Malignant disease & immunosuppression |
Submission type | N/A |
Status | Excluded due to NICE appraisal |
Date of issue | 21/03/2013 |
NICE guidance |